Drug Profile

Insulin analog - Invictus Therapeutics

Latest Information Update: 01 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Invictus Therapeutics
Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

22 Jan 2026 Insulin analog - Invictus Therapeutics is available for licensing as of 12 Jan 2026. https://www.invictustx.com/
12 Jan 2026 Preclinical trials in Diabetes mellitus in USA (unspecified route) prior to January 2026
12 Jan 2026 Invictus Therapeutics plans a phase I first in human trial for Diabetes mellitus in Germany

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com